CMC Considerations for Biotechnology Product Development: A Regulatory Perspective

(56:31)

CMC Considerations for CAR T Cell Product Development

(29:42)

CMC Considerations for Oncolytic Viral Product Development

(30:29)

CMC Considerations For mRNA Manufacturing

(8:44)

CMC Considerations for Developing an Effective mRNA/LNP Therapeutic

(26:29)

Biologics CMC Considerations For Advanced Therapies – Cell And Gene

(1:1:23)

CMC Considerations For In-Human Studies with Drs. Edith Perez And Nathan Ihle

(45:18)

The Key CMC Considerations in Breakthrough Drug Development

(3:59)

Chemistry, Manufacturing Controls (CMC) in an Investigational New Drug (IND) (7/14) REdI 2017

(1:20:20)

CMC Considerations for Commercial-Ready ADC Manufacturing Processes to Enable Accelerated Timelines

(17:37)

Get there Faster - Therapeutics Development to CMC IND Submission

(1:2:22)

CMC Regulatory Considerations for Oligonucleotides and Peptides Similarities and Differences

(29:8)

CDMO's Role In CMC \u0026 Regulatory Considerations

(7:30)

Chemistry, manufacturing and controls (CMC)

(2:12)

WEBINAR: Overview of CMC Biotechnology Webinar - Dr Nadine Ritter

(36:49)

A Q\u0026A On CMC In mRNA Manufacturing

(24:5)

Vol 45: Considerations for Developing Pediatric Drug Products: A CMC Perspective

(11:43)

Overview of Post-approval Chemistry, Manufacture, and Controls (CMC) Changes to an NDA - REdI 2020

(27:10)

Vol 41: Implications of Recent Regulatory Changes on CMC Drug Development: A Look Ahead

(10:30)

What Does CMC Regulatory Affairs Do?

(18:24)